A Review on Tenable Effects on Persistent use of Proton Pump Inhibitors

Abstract

ABSTRACT

Proton pump inhibitors (PPIs) are one of the most prescribed class of drugs today and are used for patients with an array of gastroenterological conditions that include gastroesophageal reflux, peptic ulcer disease, Helicobacter pylori infection, and Barrett's esophagus. PPIs act on the gastric acid production by inhibition of the gastric H+/K+‐ATPase via covalent binding to cysteine residue of this proton pump, affecting the final step of acid production. They are the most potent opponent of gastric acid production. Usage of PPIs steadily and extremely increased after starting clinical use for treatment of acid-related diseases, and they are now some of the most often prescribed drugs throughout the world with large numbers of affected patients provided enduring treatment with PPI administration for several years. Along with their esteem, adverse events possibly related to long-term administration of PPIs have been reported, though the level of risk is not high. As the quality of patient life is crucial, caution in prescribing PPIs should be used in patients at elevated risk for any of these conditions like kidney disease and low magnesium levels, serum creatinine and magnesium levels should probably be monitored in patients using PPIs, especially those using high doses. If prolonged treatment is required, consideration should be given to alternative medical or surgical therapy. The cautious prescriber should be aware of those potential risks and properly balance the benefits of PPI use and their patient's individual symptoms and comorbidities.

Keywords: PPIs, osteopenia, hypomagnesaemia, microbiome, hepatic encephalopathy.

Cite this Article: Santhi Sri, Sai Theja Guduru, K. Yalla Reddy, M. Alagusundaram. A Review on Tenable Effects on Persistent use of Proton Pump Inhibitors. International Journal of Cell Biology and Cellular Processes. 2019; 5(2): 1–12p.